Related references
Note: Only part of the references are listed.2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse et al.
DIABETES CARE (2020)
Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study
Stefano Del Prato et al.
DIABETES OBESITY & METABOLISM (2020)
Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis
Cristy R. C. Verzijl et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Clinical pharmacology of imeglimin for the treatment of type 2 diabetes
Karl Sebastian Johansson et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
Vlad Ratziu et al.
HEPATOLOGY (2020)
A novel non-PPARgamma insulin sensitizer: MLR-1023 clinical proof-of-concept in type 2 diabetes mellitus
Moon-Kyu Lee et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2020)
Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes
Kun-Ho Yoon et al.
DIABETES OBESITY & METABOLISM (2020)
Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity
Harold E. Bays et al.
OBESITY (2020)
Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy
Erin S. Morgan et al.
DIABETES CARE (2019)
The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes
Yan-Ling He et al.
DIABETES OBESITY & METABOLISM (2019)
Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
Jennifer R. Donnan et al.
BMJ OPEN (2019)
An update on the safety of SGLT2 inhibitors
Andre J. Scheen
EXPERT OPINION ON DRUG SAFETY (2019)
VK2809, a Novel Liver-Directed Thyroid Receptor Beta Agonist, Significantly Reduces Liver Fat with Both Low and High Doses in Patients with Non-Alcoholic Fatty Liver Disease: A Phase 2 Randomized, Placebo-Controlled Trial
Rohit Loomba et al.
JOURNAL OF HEPATOLOGY (2019)
The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy
Anna Thorso Larsen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Final Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the MetAP2 Inhibitor ZGN-1061 in Patients with Type 2 Diabetes
Terri Kim et al.
DIABETES (2019)
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Vanita R. Aroda et al.
DIABETES CARE (2019)
Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide
Julio Rosenstock et al.
DIABETES CARE (2019)
A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes
Yuan-Di C. Halvorsen et al.
DIABETES OBESITY & METABOLISM (2019)
A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults
Yuan-Di Halvorsen et al.
DIABETES OBESITY & METABOLISM (2019)
Sotagliflozin: First Global Approval
Anthony Markham et al.
DRUGS (2019)
Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
Pouya Saeedi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis
Yoshio Sumida et al.
HEPATOLOGY RESEARCH (2019)
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison et al.
LANCET (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Oral semaglutide for the treatment of type 2 diabetes
Maka S. Hedrington et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
Edgar D. Charles et al.
OBESITY (2019)
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial
Rohit Loomba et al.
HEPATOLOGY (2018)
A potent, selective, and orally bioavailable inhibitor of the protein-tyrosine phosphatase PTP1B improves insulin and leptin signaling in animal models
Navasona Krishnan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
G Protein-Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus
Darren M. Riddy et al.
PHARMACOLOGICAL REVIEWS (2018)
SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice
Leonardo Spatola et al.
DIABETES THERAPY (2018)
SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice
Leonardo Spatola et al.
DIABETES THERAPY (2018)
Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites
Caina Li et al.
BIOCHEMICAL PHARMACOLOGY (2018)
LIK066, a Dual SGLT1/2 Inhibitor, Reduces Weight and Improves Multiple Incretin Hormones in Clinical Proof-of-Concept Studies in Obese Patients With or Without Diabetes
Yanling He et al.
DIABETES (2018)
A Phase 1b/2a Study of Glutazumab for the Treatment of Type 2 Diabetes and Obesity
Shuqian Jing et al.
DIABETES (2018)
Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study
Robert R. Henry et al.
DIABETES CARE (2018)
A review of GLP-1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials
Vanita R. Aroda
DIABETES OBESITY & METABOLISM (2018)
Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial
Jeremy Pettus et al.
DIABETES OBESITY & METABOLISM (2018)
Dorzagliatin (HMS5552), a novel dual-acting glucokinase activator, improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes: A 28-day treatment study using biomarker-guided patient selection
Xiao-Xue Zhu et al.
DIABETES OBESITY & METABOLISM (2018)
Sotagliflozin: a dual sodium-glucose co-transporter-1 and-2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus
H. Sims et al.
DIABETIC MEDICINE (2018)
Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial
Joseph Proietto et al.
DIABETOLOGIA (2018)
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
Merlin C. Thomas et al.
DIABETOLOGIA (2018)
Development of SGLT1 and SGLT2 inhibitors
Timo Rieg et al.
DIABETOLOGIA (2018)
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
Christoph Wanner et al.
DIABETOLOGIA (2018)
Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis
Frank Tacke
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
The role of FGF21 in type 1 diabetes and its complications
Jian Zhang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2018)
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison et al.
LANCET (2018)
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
Philip Ambery et al.
LANCET (2018)
Gut hormone polyagonists for the treatment of type 2 diabetes
Sara J. Brandt et al.
PEPTIDES (2018)
Uniting GDF15 and GFRAL: Therapeutic Opportunities in Obesity and Beyond
Shannon E. Mullican et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2018)
New hope for glucokinase activators in type 2 diabetes?
Andre J. Scheen
LANCET DIABETES & ENDOCRINOLOGY (2018)
GLP-1 receptor agonists: differentiation within the class
Simeon I. Taylor
LANCET DIABETES & ENDOCRINOLOGY (2018)
Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study
Dalong Zhu et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
M. Angelyn Bethel et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
Rohit Loomba et al.
GASTROENTEROLOGY (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
Arun Sanyal et al.
LANCET (2018)
Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial
Barry Gumbiner et al.
ENDOCRINE (2018)
Advances in micro- and nanotechnologies for the GLP-1-based therapy and imaging of pancreatic beta-cells
Faruk H. Moonschi et al.
ACTA DIABETOLOGICA (2018)
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals
Tania Garito et al.
DIABETES OBESITY & METABOLISM (2018)
PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients
Par Steneberg et al.
JCI INSIGHT (2018)
Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial
Shin Fukudo et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2018)
Glycemic Targets: Standards of Medical Care in Diabetes-2018
DIABETES CARE (2018)
Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018
DIABETES CARE (2018)
Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis
Jay S. Skyler et al.
DIABETES (2017)
Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients
Xiaoping Chen et al.
JOURNAL OF DIABETES (2017)
Fibroblast Growth Factor 21-Metabolic Role in Mice and Men
Harald Staiger et al.
ENDOCRINE REVIEWS (2017)
Fructose-1,6-bisphosphatase inhibitors: A new valid approach for management of type 2 diabetes mellitus
Ramandeep Kaur et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Investigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes
Andre J. Scheen et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes
Nicole C. Goodwin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
LX2761, a Sodium/Glucose Cotransporter 1 Inhibitor Restricted to the Intestine, Improves Glycemic Control in Mice
David R. Powell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis
Yong-Chao Qiao et al.
ONCOTARGET (2017)
The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo
Yi Huan et al.
SCIENTIFIC REPORTS (2017)
Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial
Shawn E. McCandless et al.
DIABETES OBESITY & METABOLISM (2017)
FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia
Tian Lan et al.
CELL METABOLISM (2017)
Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes
Heidi Storgaard et al.
DIABETES OBESITY & METABOLISM (2017)
A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference
Sofie Gydesen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
Protein tyrosine phosphatase 1B inhibitors as antidiabetic agents - A brief review
Mansi Verma et al.
BIOORGANIC CHEMISTRY (2017)
Pharmacokinetics and Pharmacodynamics of Henagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor, in Chinese Patients with Type 2 Diabetes Mellitus
Xiaolan Yong et al.
CLINICAL DRUG INVESTIGATION (2016)
GLP-1 and Amylin in the Treatment of Obesity
T. Jorsal et al.
CURRENT DIABETES REPORTS (2016)
G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges
Kurt Ritter et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Clinical Trials, Triumphs, and Tribulations of Glucagon Receptor Antagonists
Mackenzie J. Pearson et al.
DIABETES CARE (2016)
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu et al.
GASTROENTEROLOGY (2016)
Non-alcoholic fatty liver disease and diabetes
Jonathan M. Hazlehurst et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2016)
Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
Heidi Storgaard et al.
PLOS ONE (2016)
AMPK activators: mechanisms of action and physiological activities
Joungmok Kim et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2016)
Recent progress in the development of small-molecule glucagon receptor antagonists
Matthew F. Sammons et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Role of Amylin in Type 1 and Type 2 Diabetes
Laura Hieronymus et al.
DIABETES EDUCATOR (2015)
Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes
G. Pacini et al.
DIABETES OBESITY & METABOLISM (2015)
Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes
N. B. Amin et al.
DIABETES OBESITY & METABOLISM (2015)
SHR3824, a novel selective inhibitor of renal sodium glucose cotransporter 2, exhibits antidiabetic efficacy in rodent models
Pang-ke Yan et al.
ACTA PHARMACOLOGICA SINICA (2014)
The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy
Pascale Fouqueray et al.
DIABETES CARE (2014)
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Steven E. Kahn et al.
LANCET (2014)
Gut Hormone Pharmacology of a Novel GPR119 Agonist (GSK1292263), Metformin, and Sitagliptin in Type 2 Diabetes Mellitus: Results from Two Randomized Studies
Derek J. Nunez et al.
PLOS ONE (2014)
Action and therapeutic potential of oxyntomodulin
Alessandro Pocai
MOLECULAR METABOLISM (2014)
Vascular Complications of Diabetes: Mechanisms of Injury and Protective Factors
Christian Rask-Madsen et al.
CELL METABOLISM (2013)
The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes
Gregory Gaich et al.
CELL METABOLISM (2013)
The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
Pascale Fouqueray et al.
DIABETES CARE (2013)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
R. Grempler et al.
DIABETES OBESITY & METABOLISM (2012)
Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients
V. Pirags et al.
DIABETES OBESITY & METABOLISM (2012)
The Lyn Kinase Activator MLR-1023 Is a Novel Insulin Receptor Potentiator that Elicits a Rapid-Onset and Durable Improvement in Glucose Homeostasis in Animal Models of Type 2 Diabetes
Alexander R. Ochman et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Glucokinase Activators for Diabetes Therapy May 2010 status report
Franz M. Matschnsky et al.
DIABETES CARE (2011)
The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis
D. Singh-Franco et al.
DIABETES OBESITY & METABOLISM (2011)
EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA1c levels in db/db mice and prolongs the survival of stroke-prone rats
Wenbin Zhang et al.
PHARMACOLOGICAL RESEARCH (2011)
A769662, a novel activator of AMP-activated protein kinase, inhibits non-proteolytic components of the 26S proteasome by an AMPK-independent mechanism
Daniel Moreno et al.
FEBS LETTERS (2008)
Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies
Theodore Mazzone et al.
LANCET (2008)
Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies
R Huxley et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Share Paper
